Can Thryv’s SGK1 inhibitor become the first disease-modifying therapy for long QT syndrome type 2?
Thryv Therapeutics Inc. has initiated its pivotal Phase 2/3 Wave II clinical trial for THRV-1268, a novel orally administered SGK1 inhibitor, in adult patients with Long QT Syndrome Type 2 (LQTS2). The launch builds on promising results from the earlier Wave I study and a subsequent clinical investigation, both of which demonstrated meaningful QT interval